Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,926,427
  • Shares Outstanding, K 98,969
  • Annual Sales, $ 248,070 K
  • Annual Income, $ -63,560 K
  • 60-Month Beta 2.43
  • Price/Sales 31.05
  • Price/Cash Flow N/A
  • Price/Book 40.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.01
  • Number of Estimates 4
  • High Estimate 0.03
  • Low Estimate -0.05
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +94.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.11 +5.23%
on 12/12/19
96.14 -16.69%
on 11/25/19
-1.09 (-1.34%)
since 11/13/19
3-Month
67.87 +18.00%
on 10/25/19
96.14 -16.69%
on 11/25/19
+0.80 (+1.01%)
since 09/13/19
52-Week
28.83 +177.80%
on 12/24/18
98.70 -18.86%
on 08/21/19
+44.79 (+126.88%)
since 12/13/18

Most Recent Stories

More News
SI-BONE Names Jeryl ("Jeri") Hilleman to Board of Directors

SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Jeri Hilleman has joined its...

SIBN : 19.70 (+3.36%)
NVCR : 80.09 (+2.89%)
NERV : 7.45 (-1.32%)
XENT : 21.52 (+0.19%)
AMRS : 3.26 (-6.72%)
Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a...

NVCR : 80.09 (+2.89%)
Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference

Novocure (NASDAQ: NVCR) announced today that William Doyle, Novocure's Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr. Doyle's presentation...

NVCR : 80.09 (+2.89%)
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology

Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO)...

NVCR : 80.09 (+2.89%)
NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 80.09 (+2.89%)
Novocure Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 31, 2019 / Novocure Ltd. (NASDAQ: ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 31, 2019 at 8:00 AM Eastern...

NVCR : 80.09 (+2.89%)
Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update

--First quarter ever of positive net income with $0.02 in earnings per share

NVCR : 80.09 (+2.89%)
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

FNY : 47.16 (-0.31%)
IWP : 150.50 (+0.14%)
PODD : 175.65 (+1.37%)
FCN : 111.63 (+1.74%)
NVCR : 80.09 (+2.89%)
IJK : 234.05 (-0.30%)
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

--NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years

NVCR : 80.09 (+2.89%)
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

--NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years

NVCR : 80.09 (+2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 82.63
1st Resistance Point 81.36
Last Price 80.09
1st Support Level 78.09
2nd Support Level 76.09

See More

52-Week High 98.70
Last Price 80.09
Fibonacci 61.8% 72.01
Fibonacci 50% 63.76
Fibonacci 38.2% 55.52
52-Week Low 28.83

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar